Benitec Biopharma Inc.

NASDAQ:BNTC

Biotechnology

Healthcare
$8.27 +3.05%

+$0.36 today

Market cap
$288.53M
Beta
0.28
P/E (TTM)
-12.3
EPS (TTM)
-$0.99
52W Low $9.85High $16.76

Volume 0.13M

Average 0.11M

BNTC Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Benitec Biopharma Inc.NASDAQ: BNTC

Research & Development · Q3 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q3 FY2026 research & development of $6.3M fell 3.0% year over year, behind the +1.2% change in trailing-twelve-month research & development. Sequentially, it rose 8.0% from the prior quarter. Over 3 fiscal years it compounded at +17.6% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -3.0% toward the trailing-twelve-month pace of +1.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.3M+8.0% QoQ
Last fiscal yearJun 2025
$18.33M+17.4% YoY
LTMMar 2026
$19.2M+1.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.0%——
1 year+17.4%——
3-year CAGR+17.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
18.33M USD
Year-over-year change
+17.4%
4-year CAGR
+27.1%

Research & Development vs competitors

How BNTC compares with its peers on the latest reported figures

  • BNTC's LTM Mar 2026 research & development of $19.2M is the 7th highest of the 10 companies compared; the peer median is $45.74M.
  • Its year-over-year change of +1.2% is the 5th highest of 10, against a peer median of -11.0%.
  • Over three fiscal years its annual growth of +17.6% compares with a peer median of +3.1%.
BNTC Competitors Peer median
Research & Development for BNTC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SLDBSolid Biosciences Inc.LTM Mar 2026$155.55M +43.4%+21.4%—
AUTLAutolus Therapeutics plcLTM Mar 2026$112.11M -27.3%+3.1%121.1%
NGNENeurogene Inc.LTM Mar 2026$82.4M +26.5%+16.4%—
QSIQuantum-Si incorporatedLTM Mar 2026$54.53M -11.0%-9.3%2944.3%
PRTCPureTech Health plcFY2025$45.74M -15.7%-26.7%981.8%
OCGNOcugen, Inc.LTM Mar 2026$41.48M +19.1%-10.9%928.9%
BNTCBenitec Biopharma Inc.LTM Mar 2026$19.2M +1.2%+17.6%—
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$18.85M +49.9%+8.2%127.5%
GALTGalectin Therapeutics Inc.LTM Mar 2026$10.04M -71.3%-23.4%—
XOMAXOMA Royalty Corp.LTM Mar 2026$468K -88.7%+123.7%1.3%
Peer median (excluding BNTC) $45.74M-11.0%+3.1%528.2%

Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue59K73K75K00
Cost of Revenue123K9K0343K0
Gross Profit(64K)64K75K(343K)(396K)
Gross Margin-108.5%87.7%100.0%——
Research & Development7.02M11.27M12.77M15.61M18.33M
Selling, General & Admin6.51M6.65M6.38M6.99M23.43M
Operating Expenses13.53M17.92M19.16M22.49M41.77M
Depreciation & Amortization424K392K381K343K396K
EBITDA(13.45M)(17.78M)(18.7M)(22.15M)(41.37M)
EBITDA Margin-22800.0%-24361.6%-24933.3%——
Operating Income(13.6M)(17.85M)(19.08M)(22.49M)(41.77M)
Operating Margin-23044.1%-24457.5%-25441.3%——
Interest Income000904K0
Interest Expense6K32K33K00
Other Income / Expenses(286K)(354K)(481K)739K3.85M
Income Before Tax(13.88M)(18.21M)(19.56M)(21.75M)(37.92M)
Pre-Tax Margin-23528.8%-24942.5%-26082.7%——
Income Tax Expense00000
Net Income(13.88M)(18.21M)(19.56M)(21.75M)(37.92M)
Net Margin-23528.8%-24942.5%-26082.7%——
EPS (Basic)(27.27)(19.31)(14.12)(2.68)(1.05)
EPS (Diluted)(27.27)(19.31)(14.12)(2.68)(1.05)
Weighted Avg Shares1.01M1.92M1.39M10.26M36.21M
Weighted Avg Shares (Diluted)1.01M1.92M1.39M10.28M36.21M

Benitec Biopharma Inc.

NASDAQ:BNTC

Intrinsic Alpha fair value

Locked

Current Price

$8.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.